Journal of Next Generation Sequencing & Applications

Biography

Matthew J Marton  Translational Biomarkers, Merck and Co., Inc., Rahway, NJ 07065, USA  prognosis might be less sensitive to tumor heterogeneity than RNA-based expression signatures, at least based on the performance and sensitivity of current DNA/RNA profiling technologies.

Research Interest

His research interest includes Drug Manufacturing & Research , Pharmaceuticals , Healthcare.

Relevant Topics